polyclonal granulopoietic phenotype. Except for four additional samples characterized as polyclonal, the clonality of the remaining samples was unknown.
We found that except for a G to A transition at position 58 in one of the hTERC alleles identified in one patient (see Figure 1) , who is an 85-year-old African-American female with CIMF, none of the other samples revealed any alteration in the gene. This G58A variation turns out to be a common sequence polymorphism (SNP) among African Americans. This natural sequence variation has been found to occur not only in patients with various hematological disorders (e.g., in 2/55 patients with myelodysplasia (MDS) 3 and 1/115 patient with Fanconi's anemia 4 ), but also in the general population of healthy African Americans (5/24 normal subjects in one study 3 and 8/101 in the other 5 ). This G58 nucleotide is not phylogenetically conserved in all of the known vertebrate's TERC RNAs and does not alter telomerase activity when tested in vitro. 6, 7 As this is the only sequence variation found in this cohort, we reason that mutation in hTERC gene in patients with PV, ET or other CMPDs rarely occurs and is unlikely related to telomere changes observed in some of these patients. We, therefore, speculate that the patient with the only other known hTERC variation described in our previous study (D389-390) might have been incorrectly diagnosed. 2 However, it remains possible that the observed shortened telomeres in PV or ET patients with clonal granulopoiesis might be caused by alterations in either the hTERT catalytic protein or in other telomere-or telomerase-associated protein factors. It is noteworthy that recent studies have reported a single acquired (somatic) mutation (Val617Phe) in the tyrosine kinase JAK2 gene in more than half of the patients with either ET or CIMF and in almost all patients with PV. 8 Although functional studies of JAK2 mutation confer several phenotypes that are consistent with the predicted hyperproliferative potential of cells of the CMPDs, they do not offer insights into the relationship between telomere length maintenance and disease pathogenesis. It is possible that other yet undefined genetic factors besides JAK2 may also play a role in CMPDs, in which each has clinical features that are distinct from the others. CD45 is the first prototypic receptor-like protein tyrosine phosphatase and is an essential regulator of signal transduction pathways in immune cells. 1 CD45 is one of the most abundant leukocyte cell surface glycoproteins and is considered to be expressed exclusively upon cells of the hematopoietic system. The expression of CD45 on mesenchymal stem cells (MSCs), progenitor cells exhibiting multilineage differentiation capacity and being able to generate fibroblasts, osteoblasts, adipocytes and chondrocytes, 2 has never been reported so far. Nevertheless, we had previously showed that expression of CD45 on bone marrow (BM)-derived and ex vivo-expanded MSCs can be detected on few specimens isolated from patients with hematological malignancies. The expression of CD45 was not only detected by flow cytometric analysis but was also demonstrated directly on 'fibroblast-like' cells by immunocytochemical study. The morphology of CD45 þ MSCs is similar to that of CD45 À MSCs and the multilineage differentiation potential of CD45 þ MSCs is well preserved. However, the expression of CD45 was lost after prolonged ex vivo culture. 3 
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Figure 1
Electropherogram showing the heterozygous G58A (arrow) identified in a patient with chronic idiopathic myelofibrosis.
Letters to the Editor
These data suggest that MSCs can express CD45 under certain conditions. We therefore conducted this study to see whether modifying the condition of ex vivo culture can induce expression of CD45 on other BM-derived, CD45
À MSCs. As the CD45 þ MSCs were initially identified from BM of patients of multiple myeloma in our previous study and many cytokines, such as interleukin-1 (IL-1), interleukin-6 (IL-6) and tumor necrosis factor-a (TNF-a), produced locally in the microenvironment by myeloma cells or other marrow components were well documented, 4 we firstly added IL-1, IL-6 and TNF-a of different concentrations into the culture medium to simulate the 'microenvironment' of BM of myeloma. In addition to this, the presence of a specific protein is ultimately dependent on specific gene expression, and histone acetylation and DNA methylation are closely related to the activation or silencing of a gene. A typical example of this is the regulation of CD21 expression on the B lymphocyte. 5 We subsequently added demethylating agent 5-aza-2 0 -deoxycytidine (AZA) and histone deacetylase inhibitor trichostatin acid (TSA) into the culture medium to see whether CD45 can be induced by changing epigenetic status or not.
The source of MSCs used in this study was the same as in our previous study. 3 However, they were all initially CD45 negative on both immunocytochemical study and flow cytometric analysis. The isolation and ex vivo expansion of BM-derived MSCs were based on published protocol 6 and the study was conducted under conditions approved by the Institutional Reviewing Board of China Medical University Hospital. To induce the expression of CD45 on MSCs, different concentrations of IL-1a (2, 10, 50 ng/ml), IL-6 (5, 25, 100 ng/ml), TNF-a (5, 25, 100 ng/ml; CytoLab Ltd, Rehovot, Israel), AZA (1 mM) and TSA (0.1 mM; Sigma, Munich, Germany) were added separately to the culture medium. As even minimal contamination of hematopoietic cells ('stick' to MSCs) may lead to false-positive CD45 expression of MSCs in flow cytometric analysis, in this study we used immunocytochemical staining to directly demonstrate whether CD45 can be seen on the 'fibroblast'-like MSCs after modifying culture condition.
For immunohistochemical analysis, the sterile hemocytometer cover glasses (Marienfeld, Germany) were put in culture dishes with 'modified medium' to let the cells grow on the cover glasses. Removing cover glasses from the culture dish 4-6 days later and washing with PBS when 90% confluence was reached. The cover glasses were incubated with 0.3% hydrogen peroxidase to deplete endogenous peroxidase followed by reblock with normal goat serum to reduce nonspecific binding. The cover glasses were then stained with monoclonal antibody to CD45 (BD, San Jose, CA, USA) followed by incubation with biotinylated antimouse/goat IgG antibody (Zymed, South San Francisco, CA, USA). Subsequent color development was achieved by incubating the glasses with 3,3 0 -diaminobenzidine tetrahydrochloride (DAB, Zymed). Positive staining was recognized under a microscope as brown color. We found that IL-1a, IL-6, TNF-a and TSA failed to induce CD45 expression on MSCs. However, CD45 can be induced by adding AZA to culture medium ( Figure 1) . The increased expression of CD45 after adding AZA was also demonstrated at RNA level by real-time PCR (Figure 2a ) using the following primers: forward primer (5 0 -GAAATTGTTCCTCGTCTGAT-3 0 ); reverse primer (5 0 -CTTTG CCCTGTCACAAATAC-3 0 ). The specificity of post-PCR product was further confirmed by electrophoresis (Figure 2b) .
In this study, we showed that CD45 can be induced to present on the CD45 À MSCs by adding demethylating agent AZA to the culture medium. The demonstration of CD45 directly on the 'fibroblast-like' cells by immunocytochemical studies suggested that the expression of CD45 on these MSCs was 'true positive' and was not due to contamination of hematopoietic cells. Nevertheless, not all MSC specimens can successfully express CD45 after adding AZA. By using the same protocol, CD45 was successfully induced from only one of another three different CD45 À MSC specimens. We cannot explain this discrepancy at present. As the MSCs used in the current study were isolated from different patients of hematological malignancies and at different passages of ex vivo expansion, the differences in the microenvironment from which MSCs were isolated as well as the differences in the duration of ex vivo culture may contribute to the different capacity of induction of CD45 expression. A good example of this is the differentiation potential of MSCs into cardiomyocyte-like cells being 'passage-restricted'. 7 In addition to induction of CD45 expression on MSCs itself, this study also adds new insight into the stem cell research. Firstly, CD45 can be induced on MSCs during ex vivo culture by adding demethylating agent AZA to the culture medium. It is thus possible to modify the characteristic of MSCs, and probably other stem cells as well, by means of changing the epigenetic status. It is also possible to change the fate and extend the plasticity of stem cell with this approach. Secondly, therapeutic usages of ex vivo-expanded MSCs are increasing rapidly in the recent years. Nevertheless, our study indicates that the expression of surface antigen and probably other characteristics as well can be changed when a drug (demethylating agent for example) was administered. Long-term follow-up of the nature and characteristics of the infused, ex vivo-expanded MSCs is therefore strongly recommended. Feto-maternal microchimerism has had a great impact on hematopoietic stem cell transplantation (SCT) in patients with acute leukemia, but the interpretation of studies requires consideration of the technique used, which is especially important because microchimerism is a low-frequency event and there are no standardized methods. In recent years, several groups have reported successful cases of non-T cell-depleted SCT from HLA-haploidentical family members based on fetomaternal microchimerism. [1] [2] [3] They selected donors after a microchimerism analysis based on typing using nested polymerase chain reaction with sequence-specific primers (PCR-SSP). 1, 4 Given the limited specificity of the technique, we sequenced the final products that were suspected to be noninherited maternal antigens (NIMAs) in two adult patients with acute myeloid leukemia.
Both cases involved relapsed patients undergoing haplotypemismatched peripheral blood SCT using high doses of peripheral blood CD34 þ cells together with stratified conditioning regimens. 5 
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n 0405, DRB1 n 0803. We performed nested PCR-SSP for HLA-A to detect potential microchimeric materials, that is, the NIMAs (HLA-A n 0101 and HLA-A n 0201 for the offspring in Cases 1 and 2, respectively) before SCT.
We isolated genomic DNA from the recipients' and donors' peripheral blood samples using an AccuPrep s Genome DNA Extraction Kit (Bioneer, Daejeon, Korea). We first amplified the DNA samples with a generic HLA-A locus-specific primer pair 
